Who
Alpna Seth
Director
Company insider
Files Form 4 as: Director, Keros Therapeutics; Director, Bio-Techne; Director, Seagen.
In numbers
- Trades disclosed
- 53
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $1.6M
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 26 Oct 2017
- Last trade
- 4 Jun 2026
- Last filed
- 5 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Jun 2026filed 5 Jun 2026 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Sold | $28K2,625 at $10.72 | filing |
| 4 Jun 2026filed 5 Jun 2026 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Sold | $28K2,625 at $10.72 | filing |
| 3 Jun 2026filed 5 Jun 2026 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Code A | —7,142 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,433 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,433 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Code A | —7,142 at $0.00 | filing |
| 30 Oct 2025filed 3 Nov 2025 | TECH Bio-Techneoption or derivative · Life-science tools | SEC FORM 4 Code A | —3,777 at $0.00 | filing |
| 30 Oct 2025filed 3 Nov 2025 | TECH Bio-TechneLife-science tools | SEC FORM 4 Code A | —1,640 at $0.00 | filing |
| 4 Jun 2025filed 6 Jun 2025 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,500 at $0.00 | filing |
| 4 Jun 2025filed 6 Jun 2025 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Code A | —5,250 at $0.00 | filing |
| 24 Oct 2024filed 28 Oct 2024 | TECH Bio-Techneoption or derivative · Life-science tools | SEC FORM 4 Code A | —3,511 at $0.00 | filing |
| 24 Oct 2024filed 28 Oct 2024 | TECH Bio-TechneLife-science tools | SEC FORM 4 Code A | —1,462 at $0.00 | filing |
| 30 May 2024filed 3 Jun 2024 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 14 Dec 2023filed 15 Dec 2023 | Seagenoption or derivative | SEC FORM 4 Code D | —14,250 | filing |
| 14 Dec 2023filed 15 Dec 2023 | Seagenoption or derivative | SEC FORM 4 Code D | —7,038 | filing |
| 14 Dec 2023filed 15 Dec 2023 | Seagenoption or derivative | SEC FORM 4 Code D | —3,171 | filing |
| 14 Dec 2023filed 15 Dec 2023 | Seagenoption or derivative | SEC FORM 4 Code D | —3,462 | filing |
| 14 Dec 2023filed 15 Dec 2023 | Seagenoption or derivative | SEC FORM 4 Code D | —3,676 | filing |
| 14 Dec 2023filed 15 Dec 2023 | Seagenoption or derivative | SEC FORM 4 Code D | —2,044 | filing |
| 14 Dec 2023filed 15 Dec 2023 | Seagen | SEC FORM 4 Code D | $3.0M12,953 at $229.00 | filing |
News
Reviewing Upstream Bio (NASDAQ:UPB) and Keros Therapeutics (NASDAQ:KROS)KROS · themarketsdaily.com · 12 Oct 2026
0 headlines in the last 90 days name Alpna Seth; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.